Abstract

This study compared the clinical usefulness of minodronate (50mg/4weeks) plus alfacalcidol (1μg/day) (Group M) with that of alfacalcidol alone (1μg/day) (Group A) for treating glucocorticoid-induced osteoporosis. The primary endpoints were the changes from baseline in lumbar spine (LS) bone mineral density (BMD) and the cumulative incidence of vertebral fracture at 24months; secondary endpoints included the changes from baseline in total hip (TH) BMD and bone turnover markers. Of 164 patients enrolled, 152 (Group M, n = 75; Group A, n = 77) were included in the analysis of efficacy. At each time point and at 24months, LS BMD and TH BMD were significantly higher in Group M than in Group A. The 152 patients were divided into two subgroups that were previously treated with glucocorticoids for ≤ 3months or > 3months. In both subgroups, the changes from baseline in LS BMD and TH BMD from baseline at 24months had increased more in Group M than in Group A. There were no differences found in the incidence of vertebral fracture between the groups, because the number of enrolled patients was lesser than that initially expected. In Group M, both bone formation and resorption markers significantly decreased from baseline at 3months and maintained at 6, 12, and 24months. Minodronate plus alfacalcidol was more effective than alfacalcidol alone in increasing BMD and was effective in increasing BMD for both prevention and treatment. Therefore, minodronate can be a good candidate drug for the treatment of glucocorticoid-induced osteoporosis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call